Advancing Drug Discovery Through Expert Oversight
Insilico Medicine Launches AI Longevity Board
Nobel laureate Michael Levitt joins new group to steer AI-driven drug discovery targeting the aging process.
A conceptual image showing a blue digital DNA strand being analyzed by a neural network interface in a modern laboratory.
Photo: Avantgarde News
Insilico Medicine established the first dedicated Longevity Board to oversee AI-driven research and drug discovery focused on biological aging [1]. The board aims to guide the company's strategy in developing treatments that target the fundamental processes of getting older [2]. Andrew Adams from Eli Lilly will chair the new group [1][3].
The board includes Nobel laureate Michael Levitt and other prominent researchers [1]. This group provides strategic oversight for Insilico's proprietary AI platform, which identifies novel drug targets for age-related diseases [2][3]. The company intends for this initiative to accelerate the timeline for bringing anti-aging therapies to clinical trials [1].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
prnewswire.com
https://www.prnewswire.com/news-releases/insilico-medicine-announces-industrys-first-longevity-board-to-accelerate-ai-driven-aging-research-for-drug-discovery-302748726.html
- 2.↗
tipranks.com
https://www.tipranks.com/news/private-companies/insilico-medicine-forms-longevity-board-to-steer-ai-driven-aging-drug-strategy
- 3.↗
moomoo.com
https://www.moomoo.com/hans/news/post/68618244/press-release-insilico-medicine-announces-industry-s-first-longevity-board
Related stories
View all
Topics
About the author
Avantgarde News Desk covers advancing drug discovery through expert oversight and editorial analysis for Avantgarde News.